Gilead Sciences (NASDAQ:GILD) has reportedly uncovered a significant drug-counterfeiting operation involving its HIV medications, which were tampered with and resold before reaching patients. The scheme, allegedly orchestrated by Peter Khaim, a twice-convicted medical fraudster, was run from two pharmacies in New York City. Khaim, described by Gilead as a major figure in counterfeiting, faces a new lawsuit filed this month by Gilead. The lawsuit targets Khaim and two pharmacies—71st RX and Best Scripts, based in Queens. Also Read: FDA Approves Gilead’s Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal. In ...